Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia

dc.contributor.authorSlotman, Berend J.
dc.contributor.authorClark, Mary Ann
dc.contributor.authorOzyar, Enis
dc.contributor.authorKim, Myungsoo
dc.contributor.authorItami, Jun
dc.contributor.authorTallet, Agnes
dc.contributor.authorDebus, Juergen
dc.contributor.authorPfeffer, Raphael
dc.contributor.authorGentile, PierCarlo
dc.contributor.authorHama, Yukihiro
dc.contributor.authorAndratschke, Nicolaus
dc.contributor.authorRiou, Olivier
dc.contributor.authorCamilleri, Philip
dc.contributor.authorBelka, Claus
dc.contributor.authorQuivrin, Magali
dc.contributor.authorKim, BoKyong
dc.contributor.authorPedersen, Anders
dc.contributor.authorFelter, Mette van Overeem
dc.contributor.authorKim, Young Il
dc.contributor.authorKim, Jin Ho
dc.contributor.authorFuss, Martin
dc.contributor.authorValentini, Vincenzo
dc.date.accessioned2023-02-21T12:42:15Z
dc.date.available2023-02-21T12:42:15Z
dc.date.issued2022-01-01
dc.description.abstractBackground Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology. Methods Anonymized administrative data from all 0.35T-MRgRT treatment systems in Europe and Asia were extracted for patients who completed treatment from 2015 to 2020. Detailed treatment information was analyzed for all MR-linear accelerators (linac) and -cobalt systems. Results From 2015 through the end of 2020, there were 5796 completed treatment courses delivered in 46,389 individual fractions. 23.5\% of fractions were adapted. Ultra-hypofractionated (UHfx) dose schedules (1-5 fractions) were delivered for 63.5\% of courses, with 57.8\% of UHfx fractions adapted on-table. The most commonly treated tumor types were prostate (23.5\%), liver (14.5\%), lung (12.3\%), pancreas (11.2\%), and breast (8.0\%), with increasing compound annual growth rates (CAGRs) in numbers of courses from 2015 through 2020 (pancreas: 157.1\%
dc.description.abstractprostate: 120.9\%
dc.description.abstractlung: 136.0\%
dc.description.abstractliver: 134.2\%). Conclusions This is the first comprehensive study reporting patterns of utilization among early adopters of a 0.35T-MRgRT system in Europe and Asia. Intrafraction MR image-guidance, advanced motion management, and increasing adoption of on-table adaptive RT have accelerated a transition to UHfx regimens. MRgRT has been predominantly used to treat tumors in the upper abdomen, pelvis and lungs, and increasingly with adaptive replanning, which is a radical departure from legacy radiotherapy practices.
dc.description.issue1
dc.description.issueAUG 22
dc.description.volume17
dc.identifier.doi10.1186/s13014-022-02114-2
dc.identifier.urihttps://hdl.handle.net/11443/2799
dc.identifier.urihttp://dx.doi.org/10.1186/s13014-022-02114-2
dc.identifier.wosWOS:000843128200002
dc.publisherBMC
dc.relation.ispartofRADIATION ONCOLOGY
dc.subjectMRI-guided radiotherapy
dc.subjectMR-IGRT
dc.subjectStereotactic body radiotherapy
dc.subjectSBRT
dc.subjectStereotactic ablative radiation therapy
dc.subjectSABR
dc.subjectART
dc.subjectoART
dc.subjectOn-table adaptive radiation therapy
dc.subjectCare patterns
dc.titleClinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clinical adoption patterns of 0.35 Tesla.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format

Collections